AbbVie Taiwan

AbbVie Taiwan (台灣艾伯維) is mid-tier MNC pharma in Taiwan (top 8-12 by Rx revenue) but with critical strategic context: Humira biosimilar erosion is the central global story (Humira lost US patent exclusivity 2023; multiple biosimilars in TW; revenue stepping down ~30-40% globally). AbbVie's playbook is to MIGRATE Humira patients to next-gen IL-23 (Skyrizi) and JAK (Rinvoq) — both of which are growing 50%+ annually globally. In TW: Skyrizi and Rinvoq launches across IBD (Crohn's, ulcerative colitis), psoriasis, PsA, AS, RA, atopic dermatitis are the BIG marketing investment waves 2024-2026. ALSO: AbbVie inherits significant CONSUMER footprint via Allergan Aesthetics (Botox Cosmetic, Juvederm) — this is FULL CONSUMER DTC, not Rx-restricted, sold through medical-aesthetic clinics (#1 medical-aesthetic market in Taiwan by spend). Estimated NT$200-400M Rx ad spend, PLUS separately significant Allergan Aesthetics consumer spend (likely NT$150-300M).